Arbutus Announces Pipeline Updates and Dosing of the First S

11.09.2023 - Progressing development of hepatitis B virus (HBV) compounds imdusiran (AB-729) and AB-101, an oral PD-L1 inhibitor Discontinuing all coronavirus and oral RNA destabilizer programs, including AB-343 and AB-161 Extending cash runway through Q3 2025 ... Seite 1

Related Keywords

William Collier , Arbutus Biopharma Corporation Nasdaq , Biopharma Corporation , Arbutus President , Chief Executive , Arbutus Biopharma Chart , Rbutus Biopharma Kurs , Rbutus Biopharma Aktie ,